HCFA Seeks Long-Term Data From Trials; Health Plans Prefer The Opposite
This article was originally published in The Gray Sheet
Executive Summary
Manufacturers designing clinical trials to support both premarket approval and reimbursement coverage for their devices need to demonstrate "long-term outcome measures," Grant Bagley, director of the Coverage and Analysis Group in the Health Care Financing Administration's Office of Clinical Standards and Quality, said at an Association for the Advancement of Medical Instrumentation meeting Oct. 9 in Baltimore.
You may also be interested in...
Sandoz And Samsung Celebrate Stelara Rival’s EU Approval
Sandoz and Samsung Bioepis have received final European Commission approval for their partnered Pyzchiva biosimilar rival to Stelara. But with European competition on ustekinumab due to kick off in just a matter of months, further applicants are also waiting in the wings.
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.